10-K: Neumora sets 2026 CNS catalysts; cash runway into 2027

Neumora outlined multiple 2026 readouts, detailed loan and ATM financing activity, and reported a $236.9M 2025 net loss with $182.5M in year-end cash as it advances MDD, Alzheimer’s agitation, schizophrenia and obesity programs.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as cautious: solid cash and multiple 2026 catalysts offset by a prior Phase 3 miss in MDD, a delayed obesity program, litigation overhang, and reliance on near-term binary readouts.

Future Outlook

Management plans multiple 2026 catalysts: KOASTAL-2/-3 Phase 3 topline in Q2 2026 for navacaprant, higher-dose MAD extension data for NMRA-511 and MAD data for NMRA-898 in 2H 2026, followed by a Phase 2 start for NMRA-511 and a first-in-human start for NMRA-215 in Q1 2027. The company expects to fund operations for at least the next 12 months and may utilize its ATM and debt facility as needed.

Industry Context

StockSavvy.ai notes that CNS drug development remains high risk with historically elevated Phase 3 attrition in depression. The M4 space is gaining traction post-KarXT approval (now branded Cobenfy), and Neumora’s M4 PAM shows PK/PD features consistent with once-daily dosing. In Alzheimer’s agitation, V1aR antagonists represent a differentiated approach versus antipsychotics; positive Phase 2 data would be notable versus limited options. Obesity is highly competitive with GLP-1s; a brain-penetrant NLRP3 inhibitor showing additive effects with semaglutide could be strategically interesting but is early and delayed to 2027.

Recommendation

The 10-K lays out significant 2026 catalysts but with high binary risk after a prior Phase 3 miss in MDD. Cash of $182.5M and financing options provide runway into at least Q1 2027, yet further capital is likely. Maintain a hold pending KOASTAL-2/-3 readouts and Phase 1/2 updates, which should clarify risk-reward and capital needs.

Keywords

["Neumora", "NMRA", "navacaprant", "KOASTAL", "KOR antagonist", "major depressive disorder", "NMRA-511", "V1aR", "Alzheimer’s agitation", "NMRA-898", "M4 PAM", "schizophrenia", "NMRA-215", "NLRP3", "obesity", "loan facility", "K2 HealthVentures", "ATM offering", "cash runway", "clinical catalysts"]